Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted EBT Margin of 93.63% for Q1 2026, down 40.97% sequentially from 66.42% in Q4 2025, and down 1896.0% YoY from 5.21% in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported EBT Margin for 17 years, with the latest figure at 93.63% in Q1 2026.
- Quarterly EBT Margin fell 1896.0% year-over-year to 93.63% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 68.74% (down 4111.0% YoY) and the FY2025 annual result came in at 64.16%, down 5263.0% from the prior year.
- EBT Margin retreated to 93.63% in Q1 2026 per VNDA's latest filing, from 66.42% in the prior quarter.
- Over five years, EBT Margin peaked at 14.91% in Q4 2022 and troughed at 93.63% in Q1 2026.
- A 5-year average of 21.8% and a median of 10.93% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2023 and 2025: EBT Margin surged 2141 bps in 2023, then sank 6485 bps in 2025.
- Over 5 years, EBT Margin stood at 14.91% in 2022, then tumbled by 125 bps to 3.67% in 2023, then sank by 233 bps to 12.22% in 2024, then tumbled by 444 bps to 66.42% in 2025, then slumped by 41 bps to 93.63% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 93.63%, 66.42%, and 50.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -123.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -123.46% |
| Mar 31, 2026 | -93.63% |
| Dec 31, 2025 | -66.42% |
| Sep 30, 2025 | -50.46% |
| Jun 30, 2025 | -66.34% |
| Mar 31, 2025 | -74.67% |
| Dec 31, 2024 | -12.22% |
| Sep 30, 2024 | -13.10% |
| Jun 30, 2024 | -10.93% |
| Mar 31, 2024 | -9.83% |
| Dec 31, 2023 | -3.67% |
| Sep 30, 2023 | -0.31% |
| Jun 30, 2023 | 5.63% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | 14.91% |
| Sep 30, 2022 | 8.36% |
| Jun 30, 2022 | 5.89% |
| Mar 31, 2022 | -12.57% |
| Dec 31, 2021 | 12.66% |
| Sep 30, 2021 | 15.30% |